Symplmed Completes Ownership Of Perindopril Franchise With Acquisition Of ACEON®
7/18/2014 10:27:32 AM
CINCINNATI--(BUSINESS WIRE)--Symplmed announced today that it has acquired U.S. rights to ACEON® (perindopril erbumine tablets), an angiotensin converting enzyme (ACE) inhibitor approved to treat patients with high blood pressure (hypertension) and reduce the risk of heart attack in patients with stable coronary artery disease. This acquisition completes Symplmed’s ownership of the perindopril franchise in the United States.
Help employers find you! Check out all the jobs and post your resume.
comments powered by